Method of treating and managing pregnant women with drug-induced hepatitis

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and can be used for treating and managing the pregnant women suffering drug-induced hepatitis. Establishing a diagnosis of drug-induced hepatitis requires oral administration of the herbal hepatoprotectors Carsil, or Hepabene, or the vitamin-free essential phospholipids Eslidin per os or Essentiale forte N intravenously, per os in standard doses with a cessation of any other drug-induced therapy, in the 1st trimester of pregnancy in case of observing a symptom-free increase of transaminase activity within 3 normal values and no counter-indications. In the 2nd trimester, a serum transaminase level up to 5 normal values requires prescribing ademetionine 400 mg intravenously N 7-10, then per os 1,600 mg/day. The therapeutic course makes 1 month. Ademetionine 800 mg intravenously N 10 + ursodeoxycholic acid 12 mg/kg/day are prescribed if observing the daily serum transaminase level of 5 to 10 normal values. Prescribing ademetionine 800 mg/day intravenously + ursodeoxycholic acid 12 mg/kg/day + prednisolone 90 mg/day is used for the daily serum transaminase level of more than 10 normal values. In the 3rd trimester, the daily serum transaminase level of below 5 normal values requires administering ademetionine 800 mg/day intravenously N10 + ursodeoxycholic acid 13 mg/kg/day. The transaminase level of 5 to 10 normal values requires prescribing ademetionine 800 mg/day intravenously + ursodeoxycholic acid 13 mg/kg/day + prednisolone 90 mg/day intravenously. A progressive increase of the daily transaminase level of above 10 normal values with underlying therapy with ademetionine 800 mg/day intravenously, ursodeoxycholic acid 13 mg/kg/day, prednisolone 120 mg/day intravenously with 3 days expected, a decrease of the daily transaminase level or a stabilization thereof are accompanied by continuing the therapy with the progression follow-up, including hepatic cytolysis values - an increase of the hepatic cytolysis values; an increase thereof is accompanied by prescribing the adequate therapy. The postpartum therapy is continued completely until liver function tests are normalised.

EFFECT: method enables preventing the pregnancy complications ensured by the timely diagnosis of drug-induced hepatitis in the pregnant women, the adequate drug-induced therapy differentiated by gestational age and a degree of manifestation of hepatic cytolysis and aiming at reducing a hepatic pathological process.

6 ex

 

The invention relates to medicine, namely to obstetrics and gastroenterology, and can be used to treat pregnant women with drug-induced hepatitis.

The problem is, first, significantly more frequent in Russia in General, cases of drug hepatitis in pregnant women, posing a serious threat to the health of pregnant women, pregnancy and the fetus, and, secondly, the lack of fit for practical use of treatment techniques and tactics of pregnant depending on gestational age and activity of the pathological process in the liver.

The results of the study indicate that the most frequently drug hepatitis in pregnant women are associated with the received prior to pregnancy, including in connection with IVF, or during pregnancy hormonal estrogen and progesteronelike drugs, polyvitamine-mineral complexes, preparations of iron and calcium, antibacterial drugs, non-steroidal anti-inflammatory drugs and other

All this leads to the fact that:

1. The most severe hepatic celebrated in the 3rd trimester of pregnancy. He is accompanied by high risk of complications of pregnancy - preeclampsia, acute fatty liver of pregnant women, coagulopathy, fetoplacental not what acestu and often early delivery.

2. The development of severe hepatic in the 2nd trimester of pregnancy in the absence of adequate treatment is an indication for premature termination of pregnancy for medical reasons.

3. In the 1st trimester forecast less serious. Provided dynamic surveillance and response to treatment" (the waiting period up to 14 days when transaminase levels <10 standards) acceptable prolongation of pregnancy.

4. Cholestatic variant hepatic flows easier than cytolytic, but permitted slower and often causes coagulopathy.

5. Poor prognosis is associated with the degree of cytolysis, hyperbilirubinemia and jaundice (mortality in acute liver failure reaches 50%).

Studies found that treatment of pregnant women with drug hepatitis should be defined:

1) the prevailing mechanism (direct hepatotoxic (cytolytic, cholestatic, or mixed) action of drugs, the toxicity of their metabolites, idiosyncrasy (individual intolerance) or immunoallergic liver disease);

2) activity of hepatitis (degree of cytolysis),

3) the presence of cholestasis,

4) period of gestation,

5) the condition of the fetus.

We identified a number of characteristics of a drug is of Apatite pregnant, define tactics of patients:

- Malosimptomnoe (weakness, itching) or asymptomatic clinic with signs expressed at the stage of impaired hepatic function.

- The prevalence of cytolytic or mixed syndrome with a tendency to progression (especially in the third trimester and after delivery).

Complex differential diagnosis due to the frequent co-morbidities, the need to perform lots of research in a short period of time with limited diagnostic capabilities.

- The need for dynamic and high activity - daily multi-component monitoring indicators of liver and hemo stasis, and more frequent monitoring of the fetus.

- Complexity of treatment involving, on the one hand, the purpose of adequate medicines, and on the other hand, the need to ensure the safety of treatment for pregnant, pregnancy and the fetus.

- Likely fatal for women and fetal complications (acute fatty liver of pregnancy, HELLP syndrome, syndrome Budd-Chiari and coagulopathy (↑) and APTT due to the progression of cytolysis and deficiency of vitamin K), especially in the third trimester.

- The need for timely decision making on early delivery or induced termination of pregnancy + high responsible the guard associated with this decision.

- The need to determine the type of delivery and method of anesthesia with regard to hepatotoxicity most anesthetics and a high probability of bleeding and DIC (advantage - caesarean section and epidural anesthesia).

- Save (the progression of symptoms of cytolysis after birth requiring prolonged therapy (including corticosteroids), and the necessity of making decisions about breastfeeding.

There is a method of treatment of hepatosis [Obstetrics: the national guide / Ed. by E. K. of Ailamazyan, C. A. Kulakov, etc. M: GEOTAR-Media. 2007. 997-998 C.] (broad and insufficiently differentiated group of liver diseases in pregnant women.

The known method involves the application of ademetionina, ursodeoxycholic acid and some other hepatoprotectors, but without specifying how they are used, the dosage, without taking into account the activity of liver cytolysis and peculiarities of prescribing drug therapy in different stages of pregnancy.

The technical result consists in preventing pregnancy complications due to timely diagnosis of drug hepatitis in pregnant women, adequate, differentiated in terms of pregnancy and the severity pecan knogo cytolysis drug therapy, aimed at reduction of pathological process in the liver.

The invention consists in that in the method of treatment and tactics of pregnant women with drug hepatitis after diagnosis of drug hepatitis in the 1st trimester when asymptomatic increase of transaminase activity within 3 standards and the absence of contraindications oral taking slidin 2 capsules 3 times a day for the abolition of other drug therapy. The treatment is carried out within 1 month. In the 2nd trimester when the level of serum transaminases up to 5 standards take ademethionine 400 mg/N 7-10, then oral 1600 mg/day, treatment 1 month, when the level of serum transaminase from 5 to 10 standards - ademethionine 800 mg/N 10 + ursodeoxycholic acid 12 mg/kg/day, with the level of serum transaminases more than 10 standards - ademethionine 800 mg/day/ + ursodeoxycholic acid 12 mg/kg/day + prednisone/90 mg/day. In the 3rd trimester when the level of serum transaminases up to 5 standards take ademethionine 800 mg/day/N10 + ursodeoxycholic acid 13 mg/kg/day, when transaminase levels from 5 to 10 standards - ademethionine 800 mg/day/ + ursodeoxycholic acid 13 mg/kg/day + prednisone/90 mg/day, with increasing level of serum transaminases exceeding 10 rules take ademethionine 800 mg/day/ + ursodeoxycholic acid 15 mg/kg/day + prednisone/12 mg/day. In the absence of reducing rates of hepatic cytolysis within 3 days of conducting early delivery. In the postpartum period is taken orally ademethionine 1600 mg/day + ursodeoxycholic acid 12 mg/kg/day. Therapy continues until normalization of liver samples" +2 weeks. In all trimesters of pregnancy therapy continue when condition monitoring dynamics - reducing activity indicators of hepatic cytolysis or assigned adequate therapy when they increase.

The method is as follows.

In the 1st trimester when asymptomatic increase of transaminase activity within 3 standards and the absence of contraindications oral taking slidin 2 capsules 3 times a day for the abolition of other drug therapy. The treatment is carried out within 1 month out in weekly biochemical monitoring of serum transaminases, bilirubin, alkaline phosphatase, gamma-glutamyltranspeptidase, prothrombin, APTT, MPE, protein fractions. At higher activity of cytolysis and no response to treatment within 2 weeks of hospitalization with the decision of the question about the use of glucocorticosteroids and abortion.

In the 2nd trimester:

- when the level of serum transaminases up to 5 standards - use ademethionine (Heptral) 400 mg/N 7-10, then oral 1600 mg/su is. Treatment 1 month.

- when the level of serum transaminase from 5 to 10 standards - ademethionine 800 mg/N 10 + ursodeoxycholic acid 12 mg/kg/day.

- when the level of serum transaminases more than 10 standards - ademethionine 800 mg/day/ + ursodeoxycholic acid (Ursosan) 12 mg/kg/day + prednisone/90 mg/day.

- in the absence of positive dynamics (waiting period 5-7 days) have an abortion for medical reasons.

In the 3rd trimester:

- when the level of serum transaminases up to 5 standards - ademethionine 800 mg/day/N10 + ursodeoxycholic acid (Ursosan) 13 mg/kg/day.

when transaminase levels from 5 to 10 standards - ademethionine 800 mg/day/ + ursodeoxycholic acid (Ursosan) 13 mg/kg/day + prednisone/90 mg/day.

- with the rise in serum transaminases more than 10 rules take ademethionine 800 mg/day/ + ursodeoxycholic acid 15 mg/kg/day + prednisone/120 mg/day. In the absence of reducing rates of hepatic cytolysis within 3 days of conducting early delivery because of the high risk of complications.

In the postpartum period is taken orally ademethionine 1600 mg/day + ursodeoxycholic acid 12 mg/kg/day.

Is the short-term progression of cytolysis (usually within 5-7 days), therefore, therapy continues in full prior to normalization of liver samples" +2 weeks is whether under the supervision of a therapist, therapy is continued until normalization of liver samples" +2 weeks.

In all trimesters of pregnancy therapy continue when condition monitoring dynamics - reducing activity indicators of hepatic cytolysis or assigned adequate therapy when they increase.

After discharge from the hospital is required to actively transfer the patient to the hospital at the place of residence for further treatment and dynamic observation. In subsequent necessarily examined by a gastroenterologist to exclude chronic drug hepatitis, autoimmune hepatitis, primary biliary cirrhosis, hepatosis and biliary pathology in connection with high frequency manifestirovanne of these diseases in women undergoing drug-induced hepatitis after birth.

Example 1

Patient P., 25 years old, were treated at the Department of gynecology with a diagnosis of Pregnancy 19-20 weeks, threatened miscarriage, anemia, mild, and therefore received the treatment: the chimes, drotaverine, pentoxifylline, Riboxin, sorbifer. On a background of treatment recorded higher rates of hepatic cytolysis: ALT 138 u/l, ACT 91,7 E/L. Serological markers of viral hepatitis and autoimmune liver disease negative. Diagnosed with drug-induced hepatitis with minimal activity. Assigned treatment ademetionina at a dose of 400 mg/day/No. 7 before lifting therapy. On the 6th day of treatment normalized the rates of hepatic transaminases and after parenteral treatment the patient was transferred to the oral ingestion ademetionina at a dose of 1600 mg/day with treatment 1 month. During subsequent pregnancy at weekly dynamic monitoring of biochemical parameters, elevation of hepatic transaminases have been identified. Delivery conducted in advance in a natural way on the term 36-37 weeks due to premature rupture of membranes. The satisfactory condition of the newborn, weight 2950, After discharge from the perinatal center, the patient actively placed under observation in the clinic at the place of residence.

Example 2

Patient R., aged 27, second pregnancy 20-21 weeks. Enrolled in the perinatal center with complaints of weakness, fatigue. From the anamnesis: 3 weeks prior to admission, the patient suffered acute bronchitis, and therefore received outpatient treatment with Ceftriaxone and paracetamol. On the background of the treatment, the symptoms of bronchitis was stopped, but continued weakness, fatigue, diagnosed elevation of hepatic transaminases: ALT 238 u/l, ACT 221 u/l, alkaline phosphatase 390 u/l, and therefore directed the women's advice for hospitalization in the Republican perinatal center. On physical examination, body weight is aziende 65 kg, the skin is pale pink, the liver is not enlarged. Viral and autoimmune etiology of liver disease were excluded. Bad habits the patient denied. Liver ultrasound abnormalities not revealed. Diagnosed with Drug-induced hepatitis of moderate activity and treatment: ademethionine 800 mg/day/ # 10 + ursodeoxycholic acid 750 mg/day. On the background of therapy activity of serum transaminases and alkaline phosphatase were normal on the 11th day of treatment. The patient in a satisfactory condition was discharged with advice to continue treatment ademetionina 1600 mg/day orally + ursodeauxiholeva acid 750 mg/day for 1 month, under the weekly monitoring of biochemical parameters of blood. For subsequent pregnancy re-transaminase elevations have been identified. Delivery carried out in a natural way on the period of 39 weeks of pregnancy. The condition of the newborn was regarded as satisfactory, body weight was 3500, After discharge from the perinatal center, the patient actively placed under observation in the clinic at the place of residence.

Example 3

Patient N., 30 years old, came for a consultation with gestation 25-26 weeks with the new icteric staining of the sclera and 10-12-fold increase in the activity of serum ALT and ACT 2 × p is the increased level of alkaline phosphatase and GGT. In further noted moderate hyperbilirubinemia due to both factions of bilirubin. Complaints during the inspection did not show. Subjectively, the state is regarded as satisfactory, there has been interesest eyes, sensitivity to palpation in the right upper quadrant, the liver was performed at 2-3 cm from the edge of the right costal arch, potowatomi consistency, smooth, rounded edge. The viral nature (antibodies to hepatitis viruses a, b, C, D, E, cytomegalovirus, Epstein-Barr, herpes simplex) liver pathology has been excluded. Absent serum markers of autoimmune hepatitis, Wilson's disease-Konovalov, Hyper-γ-globulinemia. Alcohol use, drug use was denied. As a result, the disease is regarded as drug-induced hepatitis with high activity on the background of long-term administration of combinations of drugs (polyvitamine-mineral complexes, preparations of iron, iodine, calcium DZ, magnesium with B6). Pregnancy in women was the first, desired, previous 2 pregnancies ended in abortion.

Due to the high activity of cytolysis was prescribed treatment with prednisolone/90 mg/day in combination with ursodeauxiholeva acid (Ursosan) 750 mg/day and ademetionina (Heptral) 800 mg/day/N10, then oral 1600 mg/day). On the 5th day of treatment there was a tendency to stabilize, and then reduce the act is vnesti serum transaminases, that helped to prolong the pregnancy and to continue the treatment with a gradual reduction in the dose of prednisolone. Subsequent dynamic monitoring indicators of hepatic cytolysis gradually decreased, although not fully normalized by the time of delivery. Delivery was conducted at the 38th week of pregnancy through Caesarian (obstetric conditions) under epidural anesthesia. Complications in the postoperative period were observed. In the postpartum period, the patient continued treatment with ademetionina at a dose of 1600 mg/day and ursodeauxiholeva acid 750 mg/day. A week later, the activity of serum transaminases fully normalized, then the treatment continued outpatient up to 1 month with the subsequent cancellation of medications. During treatment breastfeeding was not conducted.

Example 4

Patient S., 25 years old, pregnant by in vitro fertilization (first pregnancy), and entered the Republican perinatal center at the time 31-32 weeks with complaints of itching of the skin for 3-4 days, weakness. During pregnancy, the patient was taken Duphaston, utrogestan, Elevit pronatal, phenols, calcemin. On physical examination: body weight of the patient 66 kg, visible mucous membranes and skin physiological painting, the liver does not HC is lichen. Biochemical blood test: ACT 60,7 u/l, ALT 64,3 u/l, alkaline phosphatase 470 u/l, GGT 75 u/l, total bilirubin 21,62 µmol/l (direct 15,89 µmol/l, indirect 5.43 mmol/l). Serological markers of viral hepatitis and autoimmune liver disease negative. Previous liver disease, alcohol and drug denied, toxic substances contact had not. Increased transaminase detected for the first time. Liver ultrasound abnormalities not revealed. Diagnosed with "drug-induced hepatitis minimal activity". Was cancelled all previous drug therapy and prescribed treatment with ademetionina 800 mg/day/ # 10 and ursodeauxiholeva acid 750 mg/day. Within 4 days the itching had stopped. The transaminase is normalized on the 9th day. On the 12th day of hospitalization the patient was discharged and scheduled outpatient treatment - ademethionine oral 1600 mg/day, and ursodeoxycholic acid 750 mg/day for two weeks, with weekly dynamic monitoring indicators of hepatic cytolysis. The increase of transaminases in the subsequent pregnancy were noted. Delivery carried out in a natural way on the period of 39 weeks. The condition of the newborn regarded as satisfactory.

Example 5

Patient K., 33, 4 pregnancies, 2 births, entered the Republican perinatal center n the term 35-36 weeks complaining of itchy skin within 2 weeks mostly at night, weakness, insomnia. From the anamnesis: the complaints appeared after treatment in the day hospital about uteroplacental insufficiency by intravenous administration of pentoxifylline, aktovegin and Riboxin. The cancellation of these drugs, the purpose of suprastin and activated charcoal effect is not brought, the increase of serum transaminases greater than 5 norms, and therefore was transferred to a perinatal centre. On physical examination: body weight of the patient 74 kg, the skin is pale pink, the liver is not enlarged. Biochemical blood test: ALT 193 u/l, ACT 569 u/l, alkaline phosphatase - 507 u/l, bilirubin total is 16.1 mmol/l, direct 13.3 µmol/l, indirect 2.8 µmol/L. ultrasound of the liver: diffuse changes of the liver parenchyma. Viral, autoimmune nature of hepatitis was excluded. Diagnosed with Drug-induced hepatitis with cholestatic component, moderate activity. Treatment: ademethionine 800 mg/day/ # 10, ursodeoxycholic acid 1000 mg/day and prednisolone/90 mg/day. During therapy were stopped itching on the 5th day, the activity of transaminases less than 5 standards recorded on the 7th day, therefore, after gradual dose reduction is completely cancelled prednisolone. By the time of delivery at 38 weeks transaminases fully normalized. Delivery conducted across the natural way. The condition of a newborn girl is satisfactory, body weight 3280, In the postpartum period in the hospital, and then continued outpatient treatment ademetionina oral 1600 mg/day and ursodeauxiholeva acid 750 mg/day to 1 month under the control liver samples".

Example 6

Patient M., 28 years old, pregnancy 31-32 weeks, the first twins male, after the procedure of in vitro fertilization. Early pregnancy preceded therapy Duphaston, utrogestan, Leviton pronatalism taking them on time 10-11 weeks were increased ALT to 85 u/l, ACT to 76 E/L. Viral, autoimmune nature of the liver disease was excluded. According to the ultrasound examination of abdominal cavity organs there is no deviation. Was diagnosed with drug-induced hepatitis with minimal activity, and therefore cancelled Duphaston and vitamin complex, utrogestan assigned intrawaginalno. Conducted therapy alidina 2 capsules 3 times a day for months. On the background of therapy indices of the activity of serum transaminases normalized. At the end of the second trimester, the patient developed anemia is mild, about which he was appointed finals and on the dates 31 week of pregnancy, the patient developed itching, mostly at night. For biochemical analysis blood was again the found increased ALT activity to 521 u/l, ACT to 498 u/l, alkaline phosphatase activity increased 1.5 times, GGT - 5 times the upper limit of normal. Hospitalized in the Republican perinatal center. At the time of admission body weight of the patient was 70 kg Viral and autoimmune etiology of hepatitis were excluded. According to the ultrasound examination of the abdominal organs, moderate hepatomegaly, diffuse changes of a parenchyma of the liver and pancreas, thickening of the walls of the gallbladder to 4 mm, the signs of biliary sludge. Was diagnosed with drug-induced hepatitis pronounced activity. Were treated ursodeauxiholeva acid 1000 mg/day, ademetionina 800 mg/day/prednisolone/120 mg/day. On the 3rd day of treatment the level of serum transaminases is stabilized, and the 7th day began to decline, which helped to gradually reduce the dose of prednisolone. The delivery was carried out by the method of cesarean section at term 37 weeks under epidural anesthesia. The surgery went without complications. The weight of one of the babies was 2700 g, other - 2350, Their condition is assessed as satisfactory. In the postpartum period, the treatment of women continued in the hospital with ademetionina oral dose of 1600 mg/day and ursodeauxiholeva acid 750 mg/day, and then out. The activity of serum transaminases completely normalized after 3 weeks.

Thus the om, the proposed method allows to diagnose drug-induced hepatitis in pregnant and to carry out adequate, which are differentiated in terms of pregnancy and the severity of hepatic cytolysis drug therapy on reduction of pathological process in the liver and prevention of pregnancy complications. To do this, use differentiated by gestation period, and activity of hepatic cytolysis drug therapy hepatic and glucocorticosteroids, which is crucial for practical use in the clinic.

Treatment and clinical management of pregnant women with drug hepatitis, namely, that after diagnosis of drug hepatitis performed in the 1st trimester when asymptomatic increase of transaminase activity within 3 standards and the absence of contraindications oral accept vegetative hepatoprotectors cars or hepabene or essential phospholipids without vitamins, slidin per os or Essentiale Forte N in/in per os in standard doses, while canceling other drug therapy, in the 2nd trimester when the level of serum transaminases up to 5 standards take oral ademethionine 400 mg/N 7-10, then per os 1600 mg/day, treatment 1 month, when the level of serum transaminase from 5 to 10 standards - Adamite the NIN 800 mg/N 10 + ursodeoxycholic acid 12 mg/kg/day, when the level of serum transaminases more than 10 standards-ademethionine 800 mg/day/ + ursodeoxycholic acid 12 mg/kg/day + prednisone/90 mg/day, in the 3rd trimester when the level of serum transaminases up to 5 standards take oral ademethionine 800 mg/day/N10 + ursodeoxycholic acid 13 mg/kg/day, when transaminase levels from 5 to 10 standards - ademethionine 800 mg/day/ + ursodeoxycholic acid 13 mg/kg/day + prednisone/90 mg/day, with progressive increases in serum transaminases more than 10 standards on therapy with ademetionina 800 mg/day/ursodeauxiholeva acid 13 mg/kg/day, prednisolone/120 mg/day with the expectation of not more than 3 days, reducing levels of transaminase or stabilization; therapy is dependent on the observation of the dynamics of indicators of hepatic cytolysis - reduction indicators of hepatic cytolysis or assigned adequate - when they increase, and in the postpartum period therapy continue in full prior to normalization of liver samples".



 

Same patents:

FIELD: medicine.

SUBSTANCE: group of inventions relates to field of veterinary. Claimed method includes obtaining antiplacental blood (APB) from young healthy horse 14 days after subcutaneous double introduction of placentolysate of cows, which contains parts of cotyledons and caruncles, with 14-day interval in dose 20 ml, and method of treatment and prevention of afterbirth retention, uterus subinvolution and postnatal endometritis in cows by application of antiplacental blood (APB), stimulating postnatal involution of genitals of newly calved cows, which is introduced subcutaneously in the area of neck two times in dose 10 ml, with 6 day interval.

EFFECT: application of antiplacental blood (APB) reduces duration of postnatal involution of genitals, which makes it possible to prevent and reduce terms of treatment of ill cows in case of afterbirth retention, uterus subinvolution and postnatal endometritis.

2 cl

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary medicine and is intended for treatment of mastitis in sheep. method includes introduction of medication, containing antibiotic and chemical therapeutic substance, at the background of subcutaneous introduction of oxytocin in dose 10 U two times with 12-hour interval and above-udder novocaine blockade in accordance with D.D.Logvinov, by double introduction of 0.25% novocaine solution in dose 0.5 ml per 1 kg of body weight, with 48-hour interval. Used is preparation, which contains antibiotic norfloxacin as antimicrobial preparation, and dioxydin as chemical therapeutic substance, and additionally 1,2-propyleneflycol, polyvinylpyrrolidone low-molecular, disodium salt of tetraacetic acid ethylenediamine (trilon B), hydrochloric acid (0.1 mol/l) to pH 4.5, water for injections with the following component ratio, wt %: dioxydin - 1.0; norfloxacin - 5.0; 1,2-propyleneflycol - 19.8; polyvinylpyrrolidone low-molecular - 0.2; disodium salt of tetraacetic acid ethylenediamine (trilon B) - 0.01; hydrochloric acid (0.1 mol/l) to pH 4.5-5.5; water for injections - to 100.0. Preparation is introduced intramuscularly in dose o.1 ml/kg of body weight two times per day until clinical recovery, for all forms of mastitis.

EFFECT: claimed invention makes it possible to provide expressed therapeutic effect.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science and aims at treating subclinical mastitis in cows. The method involves intracisternal administration of an activated physiologic saline. The activated physiologic saline is administered in the concentration of 600 mg/l in a dose of 20 ml after afternoon milking three days running. Additionally Trivyt 10 ml is intramuscularly injected on the first therapeutic day.

EFFECT: using the declared invention enables more effective treatment and reduced period of recovery.

2 tbl, 3 ex

FIELD: veterinary medicine.

SUBSTANCE: therapeutic agent is used as N,N-dimethylamino-prolinamide of oleic acid of the formula 1 , which is used as the aqueous solutions of its salts with pharmacologically acceptable acids.

EFFECT: high therapeutic effect in treatment of endometritis of animals.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and concerns a platform for the delivery of a silver ion releasing compound for treating menorrhagia. The platform comprises a physiologically inert flexible flat spiral sized up to be introduced into a female's uterine cavity, as well as comprises a tissue-necrotising amount of a solid, water-soluble silver salt. The silver ions are delivered to an endometrium to cause the endometrial tissue necrosis. The silver ions stayed inside the uterine cavity can be neutralised by sodium chloride solution delivered to the uterus, e.g. by a catheter, and the carrier can be removed from the uterus.

EFFECT: invention provides extending the range of products, as well as presents the improved agent for treating by more accurate silver nitrate delivery into the uterine cavity.

22 cl, 1 ex, 2 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and can be used for treating anaemia in pregnant women. That is ensured by determining the blood serum iron concentration. If the serum iron concentration is less than 13.0 mcmole/l, chronoferrotherapy combined with hyperbaric oxygenation (HBO) is prescribed. The chronoferrotherapy is conducted for 30-50 days with the use of the Sorbifer Durules preparation taken daily in a single dose in the evening from 8 pm to 10 pm., while the hyperbaric oxygenation is conducted within 5 sessions in the mode of 1.3-1.4 ata pure medical oxygen for 40 minutes.

EFFECT: method provides the higher clinical effectiveness by potentiating the therapeutic effect as a result of the combined action of the HBO and the anti-anaemic preparation; the method is easily reproducible and requires no material costs.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science and can be used in integrated therapy of horses suffering from postpartum acute and chronic endometritis. A method for indirect endolymphatic therapy of endometritis in horses consists in lymphotropic administration of Lydase 64 IU dissolved in 0.25% Novocaine 1 ml and then a mixture consisting of polyoxidonium 6 mg, 0.25% Novocaine 100ml, oxytocin 30 IU and a daily unit of the antibiotic gentamicin by means of a universal device for intravenous infusion in the middle of the ischiorectal fossa at a depth of 1.5-2 cm twice every 48 hours.

EFFECT: method enables providing more effective treatment of endometritis in the horses, reducing a probability of side effects and recurrences, as well as cutting the length of treatment.

1 tbl

FIELD: veterinary medicine.

SUBSTANCE: agent for optimisation of the reproductive function of cows comprises fumaric, ascorbic, succinic, and citric acid, based on the dose, mg/kg live body weight: fumaric acid - 3.0-5.0; ascorbic acid - 4.5-7.5; succinic acid - 6.0-10.0; citric acid - 1.5-2.5. The agent is environmentally safe, and its effect on the body of animals is characterized by physiological ability. It activates erythropoiesis and optimizes the redox processes, stabilizes glucose values, total lipids and cholesterol within the preferred physiological standards, supports at high level indicators of components of non-enzymatic link of the antioxidant defence system (vitamins A, C, ceruloplasmin) than consistently provides the content of toxic products of lipid peroxidation (malondialdehyde) within the physiological standards and the optimal level of non-specific resistance of animals after calving.

EFFECT: agent provides optimisation of the reproductive function of cows, reducing the time of involution of genital organs of cows after calving, increasing rate of fertilization and reduction of the length of the service period.

7 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to gynaecology, and can be used in treating such diseases as dysfunctional uterine bleeding, menorrhagia, dysmenorrhoea, endometriosis, uterine fibroid, menopausal disorders, osteoporosis and urogenital atrophy. That is ensured by presenting an urogenital system comprising a frame forming an internal cavity enclosing an insert with a therapeutically effective dose of a biologically active compound. The insert is form-stable and damage-resistant when in use. The frame has an open structure providing access to a main portion of an external portion of the insert. The frame comprises one or more retaining element for frame holding in the uterine. What is also presented is a method for making the above intrauterine system.

EFFECT: group of inventions provides an effective controlled release drug delivery for a long period of time, as well as easy and safe administration and proper removal of the preparation.

14 cl, 9 dwg

FIELD: veterinary medicine.

SUBSTANCE: method of comprehensive treatment of cows with postpartum endometritis comprises repeated subcutaneous injection of preparation of general stimulating nonspecific therapy in conjunction with symptomatic and etiotropic preparations, and the preparation of general stimulating nonspecific therapy is used as tissue biostimulant from the spleen, which is administered subcutaneously five times with an interval between injections of 48÷72 hours with increasing doses of 30, 35, 40, 45 and 50 ml.

EFFECT: enhancing the therapeutic efficacy of treatment of cows with postpartum endometritis, reducing insemination index and duration of infertility.

3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to therapy and infectious diseases, and can be used for preventing and treating bronchial asthma, complicating respiratory viral infections and other respiratory inflammatory diseases. That is ensured by a combined inhibition of p-gene of the respiratory syncytial virus (further - RSV) and anti-inflammatory murine il-5 gene; p-gene of the RSV required for the cell replication is inhibited using a created molecule of small interfering RNA (siRNA) - SEQ ID NO 1 (siP1), while anti-inflammatory murine il-5 gene is inhibited using a created molecule of siRNA - SEQ ID NO 15 (siIL4-408). They are used to develop preparations containing therapeutically effective amounts thereof to be used intranasally.

EFFECT: method enables relieving signs of the allergic inflammation and a severity of RSV-infection by inhibiting anti-inflammatory murine il-5 gene and inhibiting the RSV virus replication.

2 cl, 17 dwg, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to peptide derivatives of general formula

,

their stereoisomers, mixtures and/or pharmaceutically acceptable salts, to methods for preparing them, to pharmaceutical compositions containing them, to using them for treating, preventing and/or diagnosing conditions, disorders and/or pathologies involving sstr1, sstr2, sstr3, sstr4 and/or sstr5 somatostatin receptor expression.

EFFECT: preparing the compositions for preventing and/or diagnosing the conditions, disorders and/or pathologies involving sstr1, sstr2, sstr3, sstr4 and/or sstr5 somatostatin receptor expression.

14 cl, 5 tbl, 33 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and concerns methods of treating growth hormone or insulin-like growth factor 1 deficiency in a patient involving administering an immunogenic amount of a vaccine containing a chimeric somatostatin-14 based polypeptide bound to inactivated chloramphenicol acetyltransferase (CAT), and an adjuvant; the vaccine for treating the patient having growth hormone or insulin-like growth factor 1 deficiency; a method of treating obesity in the patient involving administering the immunogenic amount of the vaccine.

EFFECT: group of inventions provide the immunogenicity for somatostatin and higher release of endogenously produced growth hormone and/or insulin-like growth factor 1.

22 cl, 8 ex, 6 dwg, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are presented: a composition for treating cancer containing (a) a conjugate containing (i) a polypeptide vector containing an amino acid sequence min. 70% identical to AngioPep-2 (SEQ ID NO: 97); and (ii) paclitaxel or a paclitaxel analogue conjugated with the above polypeptide; (b) an optional tonicity agent; (c) a buffer agent; (d) an excipient; (e) a polyoxyethylene ester of fatty acid; and (f) 0.01-8% DMSO (versions), a method for preparing (versions), a method of treating cancer, a container comprising the above composition, and a kit comprising the container with the above composition.

EFFECT: invention differs by the fact that the declared conjugates (eg ANG 1005) may pass through the hematoencephalic barrier, be characterised by high absorption by the targeted cells, manifest higher stability or be removed from the cell in a lesser degree, while the based compositions may be dissolved in an aqueous solution; they differ by stability and the minimal decomposition at temperatures within the range of 40°C and 50°C.

53 cl, 3 dwg, 28 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to application of peptide, which has sequence originating from amino acid sequence of protein SNAP-25, for treatment of pain and/or inflammation.

EFFECT: obtaining novel composition.

9 cl, 1 dwg, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: group concerns a prolonged delivery of a compstatin analogue, as well as an optional additional active agent when released from a microscopic gel-like inclusion formed if a liquid composition containing the compstatin analogue is introduced into an extravascular space, such as a vitreous chamber of eye in a mammalian body. The invention also refers to a method of treating an individual suffering age-related macular degeneration (ARMD).

EFFECT: improving the compstatin delivery system for the complement system inhibition required for treating ARMD.

58 cl, 4 ex, 6 tbl, 5 dwg

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and pharmaceutics, and concerns a method of treating pleural mesothelioma by administering a conjugate containing a targeting peptide containing a NGR motif, and cytokine representing TNF specified in a group consisting of TNFα, TNFβ, and also refers to a pharmaceutical formulation containing the above conjugate dissolved in suitable buffers.

EFFECT: group of inventions provides the therapeutic effectiveness, relative safety and low toxicity profile for the patients.

9 cl, 2 ex, 2 tbl

FIELD: biotechnologies.

SUBSTANCE: invention proposes compounds of labyrinthpeptins A1, A2, or A3 of formula (I) , where {A}, {B}, {C}, R1-R6, m and n have the values specified in the formula of the invention. Compounds are obtained at fermentation of Actinomadura namibiensis DSM 6313 strain under acceptable conditions in cultural environment till one or more compounds of formula (I) are formed. The invention proposes the deoxyribonucleic acid (DNA) coding preprolabyrinthpeptin A2, and the deoxyribonucleic acid (DNA) coding preprolabyrinthpeptin A1, as well as preprolabyrinthpeptins A1 and A2, and prolabyrinthpeptins A1 and A2. Labyrinthpeptins of formula (I) are used for therapy of infections caused by gram-positive bacteria, virus infections and/or neuropathic pain caused by inflammation.

EFFECT: improving therapy efficiency.

24 cl, 4 tbl, 20 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dermatology and dentistry, and can be applied for treatment of lichen ruber planus of oral cavity mucosa. For this purpose at the background of traditional therapy applied is combination of two medications immunomax and gepon. Immunomax is introduced intramuscularly in dose 200 U, one time per day on 1, 2, 3, 8, 9 and 10-th days of treatment. Gepon is applied by irrigation of affected areas of oral cavity mucosa with 0.04% solution, daily during the entire treatment course.

EFFECT: method makes it possible to achieve high efficiency of treatment and contributes both to correction of immune disorders and local manifestations of disease on oral cavity mucosa.

1 ex, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and deals with application of mimotopes for treatment of β-amyloidosis, including Alzheimer's disease, where said mimotopes, are polypeptides, which contain from 4 to 20 amino-acid residues and are able to induce in vivo formation of antibodies to complete Ap 1-40/42 and short-cut from N-end forms AβpE3-40/42, Aβ3-40/42, Aβ11-40/42, AβpEl 1-40/42 and Aβ14-40/42 without impairment of physiological function of FHT.

EFFECT: group of inventions ensures reduction of risk of autoimmune diseases when introduced to subject.

29 cl, 3 ex, 4 tbl, 7 dwg

FIELD: chemistry.

SUBSTANCE: in formula (I) each of A1, A2 and A3 is independently selected from the group, consisting of O and S, R1 represents an alkyl chain with the length of 2-28 carbon atoms, R2 is selected from the group, consisting of (3-carboxy)propyl and (20carboxy)ethyl, and R3 is selected from the group, consisting of H, C1-20acyl, phosphate, phosphocholine, phosphoethanolamine, phosphoethanolamine-N-glutaric acid and phosphoserine. The invention also relates to a pharmaceutical composition, containing the said compounds, and to the application of the compounds for manufacturing a medication, intended for treatment or prevention of diseases or disorders, associated with inflammation, or for the reduction of the level of cytokine, selected from the group, consisting of interleukin-12 and interleukin-23.

EFFECT: increase of the treatment efficiency.

60 cl, 39 dwg, 18 ex

Up!